SecBot SecBot
144 ·Filed Jun 11, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001950047-26-005947
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The filing itself is routine and not directly actionable. Monitor for the executed Form 4 to confirm the sale actually occurred, the ~$1.44M amount is small relative to market cap and likely tax-motivated option exercise covering. No bearish read-through for RVMD from this isolated insider filing.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$153.87
T+0 close · Jun 11, 2026 · via day close
Latest settled
+34.74%
T+60 · $207.32
Vs SPY
+31.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $153.87entry
  2. T+1 · 5mo ago +4.02%α +2.26% · $160.06
  3. T+5 · 5mo ago +5.93%α +5.25% · $162.99
  4. T+20 · 4mo ago +21.45%α +19.67% · $186.88
  5. T+60 · 2mo ago +34.74%α +31.47% · $207.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Margaret A. Horn files Form 144 notice of intent to sell 10,000 shares (~$1.44M based on stated value). This is a relatively modest sale relative to the $30.7B market cap, representing ~0.00003% of shares outstanding. The shares are being sold to cover option exercise costs, a routine insider transaction pattern.

Key Facts

  • Director Margaret A. Horn filed Form 144 on 2026-06-11
  • Proposed sale of 10,000 shares with approximate value of $1,441,900
  • Shares to be sold through Morgan Stanley Smith Barney LLC
  • Sale is to cover costs of exercising stock options (cash exercise)
  • Horn not a named executive officer, holds board director role

Financial Impact

~$1.44M proposed sale value; director ownership stake undisclosed but likely moderate at ~$30.7B market cap

no change to core financials

Risk Factors

  • Insider may be incrementally reducing exposure ahead of any near-term clinical data readout
  • Form 144 is intent-to-sell only; sale may not execute if conditions change

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005947
Document: 0001950047-26-005947-index.html0001950047-26-005947
Document: 0001950047-26-005947.txt0001950047-26-005947

US Market Status

Market Closed · Opens in 8h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026